Amvuttra market report points to faster growth in personalized RNA therapies

The Business Research Company says the Amvuttra market is expanding on rising rare-disease awareness, better genetic screening and stronger demand for personalized medicine. North America led the market in 2025, while Asia-Pacific is projected to grow fastest over the forecast period.

Why it matters: - Amvuttra sits in a growing market for targeted RNA therapies for transthyretin amyloidosis, a rare disease with limited treatment options. - Faster diagnosis and broader use of genetic screening could bring more patients into treatment sooner. - The market’s growth may also signal wider adoption of personalized medicine and orphan-drug investment.

What happened: - The Business Research Company published a 2026 Amvuttra market report covering forecasts, innovations and regional trends. - The report says Amvuttra market growth has been supported by RNA interference advances, regulatory approvals of siRNA drugs, rising rare-disease awareness and specialist adoption of targeted therapies. - The report forecasts further growth from expanded RNA-based pipelines, higher amyloidosis diagnosis rates, improved genetic screening, increased orphan-drug funding and more long-term efficacy data. - The source text offers a free sample of the Amvuttra market report. - The source text also links to the full Amvuttra market report.

The details: - Amvuttra is a prescription siRNA therapy designed to reduce the liver’s production of transthyretin, or TTR, protein. - The drug works by targeting and degrading the messenger RNA that drives TTR synthesis. - Lowering TTR production can help prevent amyloid deposits that cause pain, weakness and reduced mobility in hereditary ATTR amyloidosis. - The report says personalized medicine is a major driver of demand because it tailors treatment to a patient’s genetic profile, environment and lifestyle. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 26 personalized medicines in 2023, compared with 12 in 2022. - The report says long-term efficacy data and orphan-drug funding are helping build confidence among clinicians and patients. - The report says improved genetic screening is supporting earlier detection and earlier treatment. - North America held the largest market share in 2025. - The region’s lead is tied to advanced healthcare infrastructure, higher rare-disease awareness and strong regulatory support. - Asia-Pacific is projected to grow fastest during the forecast period. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report frames Amvuttra less as a standalone drug story and more as part of a broader shift toward precision medicine for rare diseases. - The emphasis on screening and diagnosis suggests market growth depends not just on treatment innovation, but on finding patients earlier. - The regional split hints at a mature U.S. market and a larger growth runway in Asia-Pacific.

What's next: - The report expects continued expansion as more patients are diagnosed and more RNA-based therapies move through development. - Long-term clinical data may shape prescriber confidence and payer adoption. - Broader use of genetic screening could keep expanding the addressable patient pool. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and updated graphics.